Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

329
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
329
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

89
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
89
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

133
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
133
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

234
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
234
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

540
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
540

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An asymptomatic <i>WASF1</i> truncation reveals pathogenic mechanism and therapeutic strategy for neurodevelopmental disorders.

Frontiers in behavioral neuroscience·2026
Same author

Development and validation of a nomogram for predicting recurrence in epithelial ovarian cancer after primary cytoreductive surgery: A single-center retrospective study.

Pakistan journal of medical sciences·2026
Same author

Primary cilia protect against intervertebral disc degeneration and spine scoliosis by regulating Hedgehog-P53-mediated cell apoptosis signaling.

Journal of advanced research·2026
Same author

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Blood-glucose Profile Evaluation with a Model-based Approach using Continuous Glucose Monitoring Data.

The AAPS journal·2026
Same author

Prognostic Value of Scoring Systems in Elderly Sepsis-Associated AKI Patients: A Multicenter Retrospective Cohort Study.

Journal of intensive care medicine·2026

Related Experiment Video

Updated: Sep 19, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

349

A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD Trials.

Liang Yang1, Carolina Llanos-Paez1, Shuying Yang2

  • 1Department of Pharmacy, Uppsala University, Uppsala, Sweden.

CPT: Pharmacometrics & Systems Pharmacology
|June 19, 2025
PubMed
Summary

This study developed a combined aggregated and individual patient data (ADIPD) model for chronic obstructive pulmonary disease (COPD) trials. The ADIPD model improves covariate estimation and clinical trial simulation accuracy.

Keywords:
COPDaggregated dataaggregation biascombined modelingindividual‐patient data

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

713
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.4K

Related Experiment Videos

Last Updated: Sep 19, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

349
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

713
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.4K

Area of Science:

  • Pharmacometrics
  • Clinical Trial Analysis
  • Data Modeling

Background:

  • Model-based meta-analysis integrates aggregated data (AD) but lacks individual-level detail.
  • Individual patient-level data (IPD) is valuable but often difficult to obtain.
  • Combined modeling offers a way to leverage both AD and IPD.

Purpose of the Study:

  • To establish a combined ADIPD model for chronic obstructive pulmonary disease (COPD) clinical trials using forced expiratory volume in 1-second (FEV1) as an endpoint.
  • To explore methods for estimating interstudy variability (ISV), interindividual variability (IIV), and aggregation bias.
  • To assess the impact of covariate correlations on aggregation bias.

Main Methods:

  • Developed separate AD and IPD models, then combined them into an ADIPD model.
  • Utilized stochastic simulation and estimations (SSE) in NONMEM for parameter estimation, optimizing ISV/IIV estimation strategies.
  • Derived an approximated normal distribution for lognormal IIV to mitigate aggregation bias.

Main Results:

  • The ADIPD model successfully integrated data from 23 COPD compounds, including baseline FEV1, disease progression, placebo effects, and dose-response relationships.
  • Identified key covariates influencing baseline FEV1 and disease progression (e.g., age, sex, disease severity, smoking status).
  • Demonstrated more precise estimation of covariate coefficients in the ADIPD model compared to the AD-only model.

Conclusions:

  • Combined ADIPD modeling provides a robust framework for analyzing complex clinical trial data in COPD.
  • This approach enhances the precision of covariate effect estimation and reduces aggregation bias.
  • ADIPD modeling facilitates more informed simulations for optimizing clinical trial design and drug development.